Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Naxitamab with COG induction chemotherapy for high-risk neuroblastoma
MOH_2025-11-25_015494Phase 2Not yet recruiting
- Sponsor
- ד"ר איריס פריד
- Start
- Nov 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of naxitamab in neuroblastoma and ganglioneuroblastoma (GNB), sponsored by ד"ר איריס פריד. Primary endpoints: Safety of naxitamab plus COG induction chemotherapy and End-of-induction response after naxitamab plus induction chemotherapy. Planned start Nov 2025; status: not yet recruiting.
02
Drugs
naxitamab
03
Conditions
neuroblastomaganglioneuroblastoma (GNB)
Beyond the preview
Go deeper on MOH_2025-11-25_015494.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2025-11-25_015494.